JP2020518651A - 抗血管新生ペプチドの持続送達のための生分解性微粒子 - Google Patents

抗血管新生ペプチドの持続送達のための生分解性微粒子 Download PDF

Info

Publication number
JP2020518651A
JP2020518651A JP2019561277A JP2019561277A JP2020518651A JP 2020518651 A JP2020518651 A JP 2020518651A JP 2019561277 A JP2019561277 A JP 2019561277A JP 2019561277 A JP2019561277 A JP 2019561277A JP 2020518651 A JP2020518651 A JP 2020518651A
Authority
JP
Japan
Prior art keywords
seq
peptide
abu
microparticles
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019561277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518651A5 (https=
Inventor
ジョーダン ジェイ． グリーン
ジョーダン ジェイ． グリーン
ニランジャン パンディ
ニランジャン パンディ
アレクサンダー エス． ポーペル
アレクサンダー エス． ポーペル
ピーター エー． カンポキアーロ
ピーター エー． カンポキアーロ
ジャヨン キム
ジャヨン キム
イー． シルバ ラクエル リマ
イー． シルバ ラクエル リマ
ロン シュムエリ
ロン シュムエリ
アダム ミランド
アダム ミランド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2020518651A publication Critical patent/JP2020518651A/ja
Publication of JP2020518651A5 publication Critical patent/JP2020518651A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019561277A 2017-05-08 2018-05-08 抗血管新生ペプチドの持続送達のための生分解性微粒子 Withdrawn JP2020518651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (2)

Publication Number Publication Date
JP2020518651A true JP2020518651A (ja) 2020-06-25
JP2020518651A5 JP2020518651A5 (https=) 2021-07-26

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561277A Withdrawn JP2020518651A (ja) 2017-05-08 2018-05-08 抗血管新生ペプチドの持続送達のための生分解性微粒子

Country Status (8)

Country Link
US (1) US20200179285A1 (https=)
EP (1) EP3621597A4 (https=)
JP (1) JP2020518651A (https=)
KR (1) KR20200003859A (https=)
CN (1) CN111315364A (https=)
AU (1) AU2018266690A1 (https=)
CA (1) CA3063140A1 (https=)
WO (1) WO2018208829A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021056B1 (pt) 2017-04-06 2022-11-22 Sustain Holdings, Llc Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
AU2020248438A1 (en) 2019-03-26 2021-10-28 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP3958889B1 (en) 2019-04-22 2025-01-08 Sustain Holdings, LLC Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.

Also Published As

Publication number Publication date
US20200179285A1 (en) 2020-06-11
WO2018208829A1 (en) 2018-11-15
KR20200003859A (ko) 2020-01-10
CA3063140A1 (en) 2018-11-15
WO2018208829A8 (en) 2019-07-04
EP3621597A4 (en) 2021-06-02
EP3621597A1 (en) 2020-03-18
AU2018266690A1 (en) 2019-12-12
CN111315364A (zh) 2020-06-19

Similar Documents

Publication Publication Date Title
JP2020518651A (ja) 抗血管新生ペプチドの持続送達のための生分解性微粒子
JP2025131583A (ja) 治療用又は診断用薬剤を含む粒子並びにその懸濁液及び使用方法
JP5739908B2 (ja) 血管形成関連の眼疾患の処置のための組成物および方法
JP6282231B2 (ja) 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20130084277A1 (en) Formulations of active agents for sustained release
WO1994027630A1 (en) Cross-linked gelatin gel preparation containing basic fibroblast growth factor
Lin et al. Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration
JP2018515582A (ja) 眼の障害の処置のためのカプセル化細胞療法の使用
JP2020518651A5 (https=)
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
KR20110070850A (ko) 제어 방출성 펩티드 제형
Dahiya et al. Ocular delivery of peptides and proteins
CN115715205B (zh) 用于眼科用途的新型药物递送系统
US20240226241A1 (en) Formulations for intraocular delivery of peptides derived from type iv collagen
Kapoor et al. Long-Acting Intraocular Delivery Approaches for Biological Therapy of Age-Related Macular Degeneration
AU2019270488B2 (en) Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
Hameed et al. Controlled Release of Therapeutic Proteins
Shende et al. Unveiling the potential of drug delivery systems for tyrosine kinase inhibitors in the treatment of neovascular eye diseases
Eskandari et al. ÔØ Å ÒÙ× Ö ÔØ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210507

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110